Hepion Pharmaceuticals Inc (HEPA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

399 THORNALL STREET EDISON, NJ 08837

The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.

Data as of 2021-04-11 07:36:04 -0400
Market Cap141.017 Million Shares Outstanding76.225 Million Avg 30-day Volume4.244 Million
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-3.88 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.99912 52-week High/Low4.83 / 1.26 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from HEPA instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 38 21 80.95% 13 (0.78%) 8 (0.5%) 62.5%
13F shares: 5.464 Million 268.014 Thousand 1938.58% 1.3 Million 149.852 Thousand 767.4%
% Ownership 17.0606 2.9696 474.51% 4.0587 1.6604 144.44%
New Positions: 22 8 175.0% 8 5 60.0%
Increased Positions 7 4 75.0% 3 1 200.0%
Closed Positions 5 4 25.0% 3 1 200.0%
Reduced Positions 3 2 50.0% 1 1 0.0%
Total Calls 216.629 Thousand 45.7 Thousand 374.02% 46.7 Thousand 28.2 Thousand 65.6%
Total Puts 156.812 Thousand 591 26433.33% 26.419 Thousand 591 4370.22%
PUT/CALL Ratio 0.72 0.01 7100.0% 0.57 0.02 2750.0%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding HEPA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HEPA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

40 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CAVAN JOHN T CHIEF FINANCIAL OFFICER

  • Officer
14,800 2021-02-18 3

FOSTER ROBERT T CEO AND DIRECTOR

  • Officer
  • Director
45,259 2021-02-18 3

WIJNGAARD PETER

  • Director
30,000 2021-02-16 5

BRANCACCIO JOHN P

  • Director
7,008 2020-12-02 2

JACOB GARY S

  • Director
12,059 2020-12-01 2

BLOCK TIMOTHY M.

  • Director
0 2020-08-19 1

LIPPA ARNOLD

  • Director
0 2020-08-19 1

ADAMS THOMAS PHD

  • Director
0 2020-08-19 1

GARLIKOV DONALD E

  • 10% Owner
3,320,000 2019-03-15 0

SAPIRSTEIN JAMES CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
492,819 2018-01-03 0

SULLIVAN-BOLYAI JOHN Z CHIEF MEDICAL OFFICER

  • Officer
58,681 2017-07-06 0

HOWSON TAMAR D

  • Director
0 2017-04-10 0

CERRONE GABRIEL

  • 10% Owner
5,183,579 2016-08-17 0

HORNUNG WILLIAM KARL CHIEF FINANCIAL OFFICER

  • Officer
0 2015-06-04 0

MCGUIGAN CHRISTOPHER

  • Director
0 2014-12-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

FOSTER ROBERT T - Director - Officer CEO AND DIRECTOR

2021-02-18 16:05:53 -0500 2021-02-18 P 20,000 $2.00 a 45,259 direct -3.4632 -18.6147 -17.316 5.6277 16 -23.3766 27

CAVAN JOHN T - Officer CHIEF FINANCIAL OFFICER

2021-02-18 16:05:28 -0500 2021-02-18 P 10,000 $2.00 a 14,800 direct -3.4632 -18.6147 -17.316 5.6277 16 -23.3766 27

WIJNGAARD PETER - Director

2021-02-18 16:06:55 -0500 2021-02-16 P 10,000 $2.20 a 30,000 direct -3.4632 -18.6147 -17.316 5.6277 16 -23.3766 27

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 22:15:03 UTC -1.0172 1.0772 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 21:45:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 21:15:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 20:45:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 20:15:04 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 19:45:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 19:15:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 18:45:02 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 18:15:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 17:45:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 17:15:03 UTC -0.9966 1.0566 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 16:45:03 UTC -1.0184 1.0784 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 16:15:03 UTC -1.0184 1.0784 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 15:45:03 UTC -1.0184 1.0784 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 15:15:03 UTC -1.0184 1.0784 1700000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 14:45:02 UTC -1.149 1.209 1000000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 14:15:03 UTC -1.149 1.209 1000000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 13:45:03 UTC -1.149 1.209 1000000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 13:15:03 UTC -1.149 1.209 1000000
HEPION PHARMACEUTICALS INC HEPA 2021-04-14 12:45:03 UTC -1.149 1.209 1000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund HEPA -800.0 shares, $-1752.0 2020-12-31 N-PORT

Elevate your investments